Skip navigation


Editorial Rating

8

Qualities

  • Overview
  • Background
  • Hot Topic

Recommendation

It’s every opportunist company’s dream: a product that’s necessary to survival plus limitations on competition and other market forces that would ordinarily drive the price of that product down. These are the conditions which result in desperate people having to pay exorbitant prices for necessary medicine. Isn’t this where regulators ought to step in? In China, the regulators have stepped in to protect consumers, but they’ve had mixed success. A team of Caixin reporters and editors tells the story of the protracted battle among pharmaceutical companies, Chinese hospitals, online marketplaces, and the humble, and often quite sick, consumer. getAbstract recommends this revealing Caixin article to health care industry regulators, patients and pharmaceutical providers.

Take-Aways

  • Long-standing practices of hospitals, doctors and pharmaceutical companies have artificially inflated the price of medicine in Chinese hospitals. 
  • Competition from online retailers has driven prices down, and hospitals and pharmaceutical companies are applying pressure so online retailers will raise their prices. These efforts have been successful, and the consumer is paying the price.
  • While regulators are trying to protect consumers by banning bribery and the unnecessary surcharges affixed to medicine, hospitals and pharmaceutical companies have found ways around regulations – and prices remain high.

About the Authors

Wang Jing, Ma Danmeng, Ren Bo, Li Yan, Liu Jiaying, Zhao Jinzhao and Han Wei  are writers and editors for the Chinese business magazine Caixin.